France reports numerous coronavirus vaccine side effects


by Jeanne Smits, LifeSite News:

Government authorities asked patients and doctors not to report all side effects, manipulating the statistics.

PARIS, France, April 21, 2021 (LifeSiteNews) — As the COVID-19 vaccine “roll-out” continues to proceed in France, the National Drug Agency (Agence nationale du médicament, ANSM) has released new figures showing that during the last week it has assessed, from April 2 to April 8, nine new cases of severe thrombosis (blood clots) linked to the AstraZeneca shot were registered. Of these, four resulted in death. TRUTH LIVES on at

23 cases of thrombosis and blood clots, and a total of 8 deaths, have now been ascribed to the newly named Vaxzevria AstraZeneca mRNA vaccine, as well as a total of 15 facial paralyses; further neurological damage had also been noted in other vaccinated people, but they have since recovered.

Earlier this month, the Tours region of France saw an unheard-of volume of reported adverse effects, mainly with the AstraZeneca shot which has been primarily given to younger people who have more violent immune reactions.

Things even got so bad that people in Touraine with adverse effects were being asked not to report them if they were not very serious.

“By the end of March, in 3 months, we had the same volume of activity as for the whole year 2020: we had received about 1,400 reports, including a large proportion related to vaccines, up to 200 per week, with a peak from 15 to 21 March with more than 200,” explained Dr. Annie-Pierre Jonville-Baré, head of the pharmacovigilance agency (CRPV) of Tours and president of the national network of CRPVs. “There have been very few Moderna and Pfizer jabs in the region, with few reports. The younger people are, the more they have reactogenic effects — that is to say fever, and muscle pain that lasts 24 or 48 hours. Since at the beginning we vaccinated the elderly in retirement homes, these effects, which are not serious and very transient, were hardly ever seen. We expected this increase in reports with the AstraZeneca vaccine, but not to this extent,” she said, adding, “We communicate a lot to ask patients not to declare everything and the ARS (Regional Health Agency) does the same thing at the level of doctors, so the volume has decreased but the situation remains tense.”

By April 8, the French Higher Health Authority (Haute autorité de santé) recommended that people who had received a first injection of AstraZeneca — some 530,000 people at the time — get a different booster jab (Pfizer or Moderna). It should be recalled that all these so-called vaccines are still in the experimental phase and that the mixing of two different gene therapy techniques has not been assessed at all for safety and efficacy.

In some French homes for the elderly, COVID-19 clusters are now appearing among residents and caregivers who actually got the experimental vaccines. In Auzances, in the depopulated Creuse region near Limoges, 24 residents and 14 employees tested positive at the end of March: it was the first time since the beginning of the Wuhan virus crisis that this had happened. Three of the elderly patients died of the South-African or Brazilian variant — two had been fully vaccinated.

The director of the home told the press that the patients who had died were over 90 and had multiple comorbidities and were already very frail when they contracted the virus. But it was precisely these people the experimental vaccines are supposed to protect from severe cases of COVID.

As suspicion grows regarding the AstraZeneca Vaxzevria shot, the European Medicines Agency (EMA) approved the Johnson & Johnson shot for the whole of the European Union, at the same time admitting that “very rare” blood clotting is linked to the use of the American vaccine, and that this is very similar to the incidents recorded with AstraZeneca. The risk-benefit ratio is in favor of using the jab, according to the EMA. French health minister Olivier Véran declared on Tuesday that France “needs” both the controversial shots in order to keep up with its vaccination schedule.

With this, the EMA moved faster than the U.S. to approve the use of the Johnson & Johnson vaccine.

Read More @